Literature DB >> 14598330

Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.

Rolf W Sparidans1, Linda Silvertand, Frits Dost, Joost Rothbarth, Gerard J Mulder, Jan H M Schellens, Jos H Beijnen.   

Abstract

A simple, sensitive and selective reversed-phase liquid chromatographic assay has been developed and validated for the anti-cancer agent melphalan in perfusate, liver and tumour tissue originating from isolated rat liver perfusion studies. Melphalan was extracted from the matrix using ice-cold methanol. The drug and the internal standard, propylparaben, were detected using ultraviolet absorbance at 262 nm. The assay has been validated in the 0.05-25 microg/mL range for perfusate; the lower limit of quantification (LLQ) is 0.05 microg/mL in perfusate and 0.25 ng/mg in liver and tumour tissues. Accuracies ranged from 89 to 110% and the inter-assay precisions were all below 15% (20% at the LLQ). Melphalan in a biological matrix has to be processed between 0 and 4 degrees C and is stable under all relevant processing and storage conditions tested. The assay has been exhaustively used in isolated liver perfusion studies with the drug demonstrating its applicability. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598330     DOI: 10.1002/bmc.273

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  1 in total

1.  Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.

Authors:  Eleonora M de Leede; Mark C Burgmans; T Susanna Meijer; Christian H Martini; Fred G J Tijl; Jaap Vuyk; Arian R van Erkel; Cornelis J H van der Velde; Ellen Kapiteijn; Alexander L Vahrmeijer
Journal:  Cardiovasc Intervent Radiol       Date:  2017-04-27       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.